167 related articles for article (PubMed ID: 36334295)
1. Leptomeningeal metastases in glioma revisited: incidence and molecular predictors based on postcontrast fluid-attenuated inversion recovery imaging.
Park YW; Han K; Park JE; Ahn SS; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
J Neurosurg; 2023 Jul; 139(1):38-48. PubMed ID: 36334295
[TBL] [Abstract][Full Text] [Related]
2. Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities.
Park YW; Han K; Kim S; Kwon H; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
J Neurooncol; 2023 Mar; 162(1):59-68. PubMed ID: 36841906
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion.
Kanazawa T; Minami Y; Takahashi H; Fujiwara H; Toda M; Jinzaki M; Yoshida K; Sasaki H
Neurosurg Rev; 2020 Aug; 43(4):1211-1219. PubMed ID: 31402410
[TBL] [Abstract][Full Text] [Related]
4. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
5. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
6. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.
Bahrami N; Hartman SJ; Chang YH; Delfanti R; White NS; Karunamuni R; Seibert TM; Dale AM; Hattangadi-Gluth JA; Piccioni D; Farid N; McDonald CR
J Neurooncol; 2018 Sep; 139(3):633-642. PubMed ID: 29860714
[TBL] [Abstract][Full Text] [Related]
8. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
Doig D; Kachramanoglou C; Dumba M; Tona F; Gontsarova A; Limbäck C; Jan W
Clin Radiol; 2021 Oct; 76(10):785.e9-785.e16. PubMed ID: 34289936
[TBL] [Abstract][Full Text] [Related]
10. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
11. Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O
Zhang S; Sun H; Su X; Yang X; Wang W; Wan X; Tan Q; Chen N; Yue Q; Gong Q
J Magn Reson Imaging; 2021 Jul; 54(1):197-205. PubMed ID: 33393131
[TBL] [Abstract][Full Text] [Related]
12. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
[TBL] [Abstract][Full Text] [Related]
13. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
14. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
16. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
17. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.
Mancini L; Casagranda S; Gautier G; Peter P; Lopez B; Thorne L; McEvoy A; Miserocchi A; Samandouras G; Kitchen N; Brandner S; De Vita E; Torrealdea F; Rega M; Schmitt B; Liebig P; Sanverdi E; Golay X; Bisdas S
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2377-2391. PubMed ID: 35029738
[TBL] [Abstract][Full Text] [Related]
18. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
[TBL] [Abstract][Full Text] [Related]
19. MRI and CT Identify Isocitrate Dehydrogenase
Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
[TBL] [Abstract][Full Text] [Related]
20. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
